Iohexol
Omnipaque (iohexol) is a small molecule pharmaceutical. Iohexol was first approved as Omnipaque 180 on 1985-12-26.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Omnipaque (discontinued: Omnipaque, Oraltag)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iohexol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OMNIPAQUE 180 | GE Healthcare | N-018956 RX | 1985-12-26 | 1 products, RLD, RS |
| OMNIPAQUE 240 | GE Healthcare | N-018956 RX | 1985-12-26 | 1 products, RLD, RS |
| OMNIPAQUE 300 | GE Healthcare | N-018956 RX | 1985-12-26 | 1 products, RLD, RS |
| OMNIPAQUE 350 | GE Healthcare | N-018956 RX | 1985-12-26 | 1 products, RLD, RS |
| OMNIPAQUE 140 | GE Healthcare | N-018956 RX | 1988-11-30 | 1 products, RLD, RS |
| OMNIPAQUE 9 | GE Healthcare | N-018956 RX | 2018-04-17 | 1 products, RLD, RS |
| OMNIPAQUE 12 | GE Healthcare | N-018956 RX | 2018-04-17 | 1 products, RLD, RS |
| OMNIPAQUE 300 | GE Healthcare | N-020608 RX | 1995-10-24 | 1 products |
| OMNIPAQUE 350 | GE Healthcare | N-020608 RX | 1995-10-24 | 1 products |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bl-contrast | unapproved drug other | 2024-08-01 |
| omnipaque | New Drug Application | 2024-10-18 |
| oraltag | New Drug Application | 2023-01-05 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
153 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | — | — | — | 1 | — | 1 |
| Healthy volunteers/patients | — | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colonic polyps | D003111 | — | K63.5 | — | 1 | 1 | — | — | 1 |
| Polyps | D011127 | EFO_0000662 | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 2 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Iohexol |
| INN | iohexol |
| Description | Iohexol is a benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position. It has a role as a radioopaque medium, an environmental contaminant and a xenobiotic. It is an organoiodine compound and a benzenedicarboxamide. |
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I |
Identifiers
| PDB | — |
| CAS-ID | 66108-95-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200455 |
| ChEBI ID | 31709 |
| PubChem CID | 3730 |
| DrugBank | DB01362 |
| UNII ID | 4419T9MX03 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,773 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bl-contrast, Omnipaque
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,466 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use